Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276) Free Cash Flow 2021–2025

Name: Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276) free cash flow history 2021-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Jiangsu Hengrui Pharmaceuticals Co.,Ltd annual free cash flow for fiscal 2025 was CNY 8.3 billion, an increase of 51.7% from CNY 5.5 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

1276 Annual Free Cash Flow

Free Cash Flow (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	CNY 8.3B	CNY 5.5B	CNY 6.2B	(CNY 727M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1276 Quarterly Free Cash Flow

Free Cash Flow (quarterly)	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Free Cash Flow	CNY 82M	CNY 878M	CNY 3.2B	(CNY 147M)	CNY 2.4B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Free Cash Flow at Comparable Companies

4507 Free Cash Flow — Shionogi & Co., Ltd.
4523 Free Cash Flow — Eisai Co., Ltd.
4151 Free Cash Flow — Kyowa Kirin Co., Ltd.
4506 Free Cash Flow — Sumitomo Pharma Co., Ltd.
4540 Free Cash Flow — Tsumura & Co.
4516 Free Cash Flow — Nippon Shinyaku Co., Ltd.

More 1276 metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS

All 1276 financial statements → Interactive 1276 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.